Endocrine Abstracts

Objectives: To describe the prevalence of liver steatosis in a cohort of patients with Cushing’s disease.Methods: Cross-sectional descriptive study. We included 59 patients with Cushing’s disease from our cohort of patients who underwent a Fibroscan to analyze the degree of hepatic steatosis (CAP measured in dB/m) and liver fibrosis (fibrosis measured in kPa). Biochemical algorithms of liver steatosis and fibrosis were assessed.<p class="ab...

Objectives: The transition from the paediatric age to the adult is a particularly vulnerable period in patients with metabolic congenital diseases (mcd). In andalusia two adults’ units exist (seville and malaga) for the follow-up of these patients. Our aim in this study was to evaluate the current series of attended patients.Material and methods: We evaluated all patients transferred to the adult units since 2008. The clinical records were analyzed ...

IntroductionCushing’s disease is the result of prolonged exposure to excess cortisol caused by a pituitary tumor, known as corticotropinoma, which hypersecretes adrenocorticotropin (ACTH). Treatment with somatostatin analogs (SSA) has been shown to reduce hormone secretion and, to a lower extent, tumor growth in some subtypes of pituitary tumors, such as growth hormone secreting tumors. However, SSA are commonly ineffective in corticotropinomas. Pre...

Background: Cushing’s disease is the result of prolonged and excessive exposure to cortisol caused by a pituitary tumor. Treatment with somatostatin analogs (SSA), which can reduce hormone secretion and tumor growth in other pituitary tumors (e.g., somatotropinomas), is usually ineffective in corticotropinomas. Previous studies indicated that presence of the truncated SST5TMD4 receptor variant is associated with a lack of response to SSA in acromegaly; but, its presence a...